Share on StockTwits

Galectin Therapeutics (NASDAQ:GALT) CFO Jack W. Callicutt purchased 1,000 shares of the stock on the open market in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average price of $4.55 per share, for a total transaction of $4,550.00. Following the purchase, the chief financial officer now directly owns 1,260 shares in the company, valued at approximately $5,733. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Galectin Therapeutics (NASDAQ:GALT) traded up 3.69% during mid-day trading on Friday, hitting $4.78. The stock had a trading volume of 404,471 shares. Galectin Therapeutics has a 52-week low of $4.28 and a 52-week high of $19.11. The stock has a 50-day moving average of $10.20 and a 200-day moving average of $12.76. The company’s market cap is $105.4 million.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.17) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.04. On average, analysts predict that Galectin Therapeutics will post $-1.03 earnings per share for the current fiscal year.

A number of research firms have recently commented on GALT. Analysts at Aegis downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 1st. Separately, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Galectin Therapeutics in a research note on Tuesday, July 29th. Finally, analysts at MLV & Co
cut their price target on shares of Galectin Therapeutics from $27.00 to $15.00 in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock.

Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.

Receive News & Ratings for Galectin Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.